{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T22:18:56Z","timestamp":1781129936499,"version":"3.54.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Hematopoietic progenitor kinase 1 (HPK1) is a member of the mitogen-activated protein kinase kinase kinase kinase (MAP4K) family. It has been reported that HPK1 negatively regulates the activation of T cells. Several compounds have been developed and tested in clinical trials to target HPK1 for cancer immunotherapy. However, whether kinase inhibition is sufficient to eliminate the immunosuppressive function of HPK1, particularly in T cells, remains elusive.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study, genetic tools were used to edit the human T lymphocyte cell line Jurkat. The activation of HPK1-null cells, HPK1-wildtype cells and HPK1-kinase-inactive cells was compared through ectopic expression of HPK1 in HPK1 knockout cells or direct HPK1 mutation. Besides genetic validation, a series of compounds that selectively target HPK1 (with or without HPK1-degradation activity) were used to assess the potential scaffold function of HPK1 in regulation of human primary T cell activation and cytotoxic activity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results and conclusion<\/jats:title><jats:p>Augmented T-cell receptor (TCR)-induced activation in HPK1-knockout Jurkat cells was inhibited by complementation of wildtype, but not kinase-dead HPK1. HPK1 K46E-knockin and K46*-knockin Jurkat cells showed comparable levels of enhanced TCR-induced activation compared with control HPK1-wildtype Jurkat cells. Similarly, HPK1 kinase inhibitor (Compound 1) and cereblon-based (CRBN-based) HPK1 degrader (Compound 2) elicited similar degrees of maximum TCR-induced activation in primary human peripheral blood T cells. In summary, the results of this study suggested that HPK1 kinase inhibitor may be sufficient for HPK1 targeting in T cell mediated cancer immunotherapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1449106","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T07:09:21Z","timestamp":1738825761000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["HPK1 kinase inhibitor: a sufficient approach to target HPK1 to modulate T cell activation in cancer immunotherapy compared with degraders"],"prefix":"10.3389","volume":"16","author":[{"given":"Qin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haimei","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.10.18.2251","article-title":"Human HPK1, a novel human hematopoietic progenitor kinase that activates the JNK\/SAPK kinase cascade","volume":"10","author":"Hu","year":"1996","journal-title":"Genes Dev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1996.tb01093.x","article-title":"HPK1, a hematopoietic protein kinase activating the SAPK\/JNK pathway","volume":"15","author":"Kiefer","year":"1996","journal-title":"EMBO J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M101485200","article-title":"Involvement of hematopoietic progenitor kinase 1 in T cell receptor signaling","volume":"276","author":"Ling","year":"2001","journal-title":"J Biol Chem"},{"key":"B4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S1074-7613(00)80192-2","article-title":"HPK1 is activated by lymphocyte antigen receptors and negatively regulates AP-1","volume":"12","author":"Liou","year":"2000","journal-title":"Immunity"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.25.6.2364-2383.2005","article-title":"Activation of hematopoietic progenitor kinase 1 involves relocation, autophosphorylation, and transphosphorylation by protein kinase D1","volume":"25","author":"Arnold","year":"2005","journal-title":"Mol Cell Biol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20062066","article-title":"A novel pathway down-modulating T cell activation involves HPK-1\u2013dependent recruitment of 14-3-3 proteins on SLP-76","volume":"204","author":"Bartolo","year":"2007","journal-title":"J Exp Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201103105","article-title":"Release of serine\/threonine-phosphorylated adaptors from signaling microclusters down-regulates T cell activation","volume":"195","author":"Lasserre","year":"2011","journal-title":"J Cell Biol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/ni1416","article-title":"Hematopoietic progenitor kinase 1 negatively regulates T cell receptor signaling and T cell-mediated immune responses","volume":"8","author":"Shui","year":"2007","journal-title":"Nat Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0243145","article-title":"Pharmacological inhibition of hematopoietic progenitor kinase 1 positively regulates T-cell function","volume":"15","author":"Wang","year":"2020","journal-title":"PloS One"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M707425200","article-title":"Prostaglandin E2 activates HPK1 kinase activity via a PKA-dependent pathway","volume":"282","author":"Sawasdikosol","year":"2007","journal-title":"J Biol Chem"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-2316","article-title":"Hematopoietic progenitor kinase 1 (HPK1) negatively regulates prostaglandin E2-induced fos gene transcription","volume":"101","author":"Sawasdikosol","year":"2003","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4402042","article-title":"Sustained JNK signaling by proteolytically processed HPK1 mediates IL-3 independent survival during monocytic differentiation","volume":"14","author":"Arnold","year":"2006","journal-title":"Cell Death Differentiation"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M008343200","article-title":"Caspase-mediated cleavage of hematopoietic progenitor kinase 1 (HPK1) converts an activator of NFkappaB into an inhibitor of NFkappaB","volume":"276","author":"Arnold","year":"2001","journal-title":"J Biol Chem"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0900457106","article-title":"Phosphorylation of CARMA1 by HPK1 is critical for NF-kappaB activation in T cells","volume":"106","author":"Brenner","year":"2009","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/sj.emboj.7600894","article-title":"Activation or suppression of NFkappaB by HPK1 determines sensitivity to activation-induced cell death","volume":"24","author":"Brenner","year":"2005","journal-title":"EMBO J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.310946","article-title":"Down-regulation of B cell receptor signaling by hematopoietic progenitor kinase 1 (HPK1)-mediated phosphorylation and ubiquitination of activated B cell linker protein (BLNK)","volume":"287","author":"Wang","year":"2012","journal-title":"J Biol Chem"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c01571","article-title":"Design, synthesis, and pharmacological evaluation of isoindoline analogues as new HPK1 inhibitors","volume":"66","author":"Xie","year":"2023","journal-title":"J Medicinal Chem"},{"key":"B18","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.08.001","article-title":"Hematopoietic progenitor kinase1 (HPK1) mediates T cell dysfunction and is a druggable target for T cell-based immunotherapies","volume":"38","author":"Si","year":"2020","journal-title":"Cancer Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c01906","article-title":"Discovery of novel PROTAC-based HPK1 degraders with high potency and selectivity for cancer immunotherapy","volume":"67","author":"Zhang","year":"2024","journal-title":"J Med Chem"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202411454","article-title":"An oral PROTAC targeting HPK1 degradation potentiates anti-solid tumor immunity","author":"Yao","year":"2024","journal-title":"Adv Mater"},{"key":"B21","volume-title":"Anti-PD-L1 antibodies and their use as therapeutics and diagnostics","author":"Kang","year":"2020"},{"key":"B22","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41392-021-00823-w","article-title":"T cell receptor (TCR) signaling in health and disease","volume":"6","author":"Shah","year":"2021","journal-title":"Signal Transduction Targeted Ther"},{"key":"B23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.celrep.2018.09.012","article-title":"The kinase activity of hematopoietic progenitor kinase 1 is essential for the regulation of T cell function","volume":"25","author":"Hernandez","year":"2018","journal-title":"Cell Rep"},{"key":"B24","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1146\/annurev.immunol.26.021607.090404","article-title":"Death by a thousand cuts: granzyme pathways of programmed cell death","volume":"26","author":"Chowdhury","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.12688\/f1000research","article-title":"Cancer immunosurveillance by CD8 T cells","volume":"9","author":"Crispin","year":"2020","journal-title":"F1000Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2174\/156800907780006841","article-title":"T cell costimulatory and inhibitory receptors as therapeutic targets for inducing anti-tumor immunity","volume":"7","author":"Foell","year":"2007","journal-title":"Curr Cancer Drug Targets"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203116","article-title":"Caspase-mediated cleavage and functional changes of hematopoietic progenitor kinase 1 (HPK1)","volume":"18","author":"Chen","year":"1999","journal-title":"Oncogene"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1449106\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T07:09:27Z","timestamp":1738825767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1449106\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":27,"alternative-id":["10.3389\/fimmu.2025.1449106"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1449106","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]},"article-number":"1449106"}}